Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THIS: Rivaroxaban for Thromboprophylaxis in Sickle Cell Disease with CVC
NCT05033314Phase 3Terminated
- Sponsor
- University Health Network
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in venous thromboembolism (VTE), catheter-related thrombosis (CRT), sponsored by University Health Network. Started Jun 2022; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on NCT05033314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033314.